WebFounded Date 2024. Founders Daniel Teper. Operating Status Active. Legal Name Cytovia Holdings, Inc. Company Type For Profit. Contact Email … The CEO of Cytovia Therapeutics Dr. Daniel Teper joins The Watchlist to discuss the company's focus on building a next-generation immuno-oncology therapeutics platform. The company was founded in 2024, and develops NK-cell and NK-engager antibody platforms to improve tumor-specific targeting in oncology patients. Dr. …
Washington, DC 20420 Transmittal Sheet October 9, 2024
WebFeb 16, 2024 · Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, … WebFeb 16, 2024 · Cytovia Therapeutics and Cellectis, a clinical stage cell therapy company announced a $760 million research and development collaboration to develop … cytoprotectives
Cytovia Therapeutics CipherBio
WebJan 13, 2024 · Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of … WebFeb 16, 2024 · Cellectis IR contact: Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, [email protected]. Cytovia Investor Relations contact: Anna Baran-Djokovic. VP of Investor ... WebApr 27, 2024 · SPAC deals appear to be continuing a trend. On April 20, Coeptis Therapeutics merged with SPAC Bull Horn Holdings in a deal worth about $175 million. Bull Horn will merge into Coeptis and be rebranded as Coeptis Therapeutics Holdings, Inc., trading on the Nasdaq under the COEP ticker symbol. binge brene brown